LobbyingPeptide Sciences lobbying by quarter
Peptide Sciences's latest lobbying report covers Q2 2026, at $210K. Its first report covers Q2 2026; the issues it reports most are Health Issues.
Peptide Sciences
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $210K
- Last 2 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q2 2026
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q2 2026 | $210K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$210K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Executive Office of the President (EOP)1 reports
- Food & Drug Administration (FDA)1 reports
- Health & Human Services, Dept of (HHS)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Miller Strategies | $210K | 1 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| ASHLEY GUNN | Special Asst to the President, Senior Director, White House Office of Cabinet Affairs. | Q2 2026 |
| NATALIE MCINTYRE | Special Assistant to the President, Office of Legislative Affairs; Sen. Bill Hagerty Legislative Director; OMB Deputy Associate Director, Legislative Affairs; ONDCP Senior Policy Advisor and White House Liaison; Sen. McConnell Legislative Assistant | Q2 2026 |
| STEFAN PASSANTINO | Deputy White House Counsel from January 2017 through September, 2018 | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Miller Strategies | $210K |
| 05/21for Q2 | Miller Strategies | Under $5,000 |